Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody-drug conjugates.
- DOI
- 10.1016/j.ctrv.2026.103173
- Published
- 2026 Jul
- Container
- Cancer treatment reviews
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ctrv.2026.103173,
title = {Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody-drug conjugates.},
author = {Wafa H and van Creij NCH and Guenther M and Noeparast M and Subiela JD and Terbuch A and Niedersuess-Beke D and Culig Z and Ormanns S and Pichler R},
year = {2026},
journal = {Cancer treatment reviews},
doi = {10.1016/j.ctrv.2026.103173},
url = {https://doi.org/10.1016/j.ctrv.2026.103173}
}RIS
TY - JOUR TI - Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody-drug conjugates. AU - Wafa H AU - van Creij NCH AU - Guenther M AU - Noeparast M AU - Subiela JD AU - Terbuch A AU - Niedersuess-Beke D AU - Culig Z AU - Ormanns S AU - Pichler R PY - 2026 JO - Cancer treatment reviews DO - 10.1016/j.ctrv.2026.103173 UR - https://doi.org/10.1016/j.ctrv.2026.103173 ER -
APA
H, W., NCH, V. C., M, G., M, N., JD, S., A, T., D, N., Z, C., S, O., & R, P. (2026). Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody-drug conjugates.. Cancer treatment reviews. https://doi.org/10.1016/j.ctrv.2026.103173
Source records
- pubmed · retrieved 2026-09-26T19:14:27.627Z